Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
Sign Up to like & getrecommendations! Published in 2020 at "JCI Insight"
DOI: 10.1172/jci.insight.139983
Abstract: Based on its clinical benefits, Trikafta — the combination of folding correctors VX-661 (tezacaftor), VX-445 (elexacaftor), and the gating potentiator VX-770 (ivacaftor) — was FDA approved for treatment of patients with cystic fibrosis (CF) carrying… read more here.
Keywords: ivacaftor; combination; tezacaftor; cftr ... See more keywords